RESUMO

We measured serum osteocalcin levels in prepubertal children with human immunodeficiency virus (HIV) infection receiving highly active antiretroviral therapy including a protease inhibitor and uninfected control children. Osteocalcin values were significantly elevated in the HIV-infected patients. Though osteocalcin serves as an index of bone formation, it likely functions as a negative regulator of bone formation. Further study is necessary to determine whether protease inhibitors normalize bone physiology or decrease bone formation and reduce bone mineral density in children receiving these therapies.

Assuntos

Terapia Antirretroviral de Alta Atividade , Osso e Ossos/metabolismo , Infecções por HIV/tratamento farmacológico , Infecções por HIV/metabolismo , Osteocalcina/sangue , Estudos de Casos e Controles , Criança , Pré-Escolar , Estudos Transversais , Feminino , Inibidores da Protease de HIV/uso terapêutico , Humanos , Masculino